Amedisys (NASDAQ:AMED) Sees Unusually-High Trading Volume

Shares of Amedisys, Inc. (NASDAQ:AMED) saw strong trading volume on Tuesday . 248,407 shares were traded during mid-day trading, a decline of 16% from the previous session’s volume of 294,641 shares.The stock last traded at $96.21 and had previously closed at $96.68.

Wall Street Analysts Forecast Growth

AMED has been the topic of several research analyst reports. Raymond James reissued a “market perform” rating on shares of Amedisys in a research note on Tuesday, March 26th. William Blair lowered Amedisys from an “outperform” rating to a “market perform” rating in a research report on Monday. Royal Bank of Canada upped their price target on Amedisys from $97.00 to $100.00 and gave the company an “outperform” rating in a research note on Monday, March 25th. Cantor Fitzgerald reiterated a “neutral” rating and issued a $101.00 price objective on shares of Amedisys in a research report on Thursday, April 25th. Finally, StockNews.com raised Amedisys from a “hold” rating to a “buy” rating in a report on Saturday, May 4th. Five investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $100.67.

Amedisys Trading Down 0.3 %

The company’s fifty day simple moving average is $93.20 and its two-hundred day simple moving average is $93.44. The company has a market capitalization of $3.15 billion, a price-to-earnings ratio of -150.33, a price-to-earnings-growth ratio of 2.25 and a beta of 0.79. The company has a quick ratio of 1.09, a current ratio of 1.09 and a debt-to-equity ratio of 0.31.

Amedisys (NASDAQ:AMED) last issued its quarterly earnings data on Wednesday, April 24th. The health services provider reported $1.03 EPS for the quarter, topping the consensus estimate of $1.02 by $0.01. Amedisys had a positive return on equity of 12.85% and a negative net margin of 0.91%. The business had revenue of $571.41 million for the quarter, compared to the consensus estimate of $565.38 million. During the same quarter last year, the business posted $1.00 EPS. The firm’s revenue was up 2.7% compared to the same quarter last year. Research analysts forecast that Amedisys, Inc. will post 4.57 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Amedisys

Several institutional investors and hedge funds have recently modified their holdings of AMED. Banque Cantonale Vaudoise acquired a new stake in Amedisys during the 1st quarter worth approximately $60,000. Covestor Ltd raised its holdings in shares of Amedisys by 134.2% during the first quarter. Covestor Ltd now owns 780 shares of the health services provider’s stock worth $72,000 after acquiring an additional 447 shares during the period. Cetera Trust Company N.A bought a new stake in Amedisys in the 4th quarter valued at $215,000. CWM LLC boosted its stake in Amedisys by 40.4% in the 4th quarter. CWM LLC now owns 2,629 shares of the health services provider’s stock worth $250,000 after purchasing an additional 757 shares during the period. Finally, Contravisory Investment Management Inc. acquired a new position in Amedisys in the 4th quarter worth $258,000. 94.36% of the stock is currently owned by institutional investors and hedge funds.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.